Biolargo Stock Today
| BLGO Stock | USD 0.18 0.01 5.26% |
PerformanceMild
| Odds Of DistressLow
|
BioLargo is selling at 0.18 as of the 29th of January 2026; that is 5.26 percent decrease since the beginning of the trading day. The stock's open price was 0.19. BioLargo has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. The performance scores are derived for the period starting the 31st of October 2025 and ending today, the 29th of January 2026. Click here to learn more.
BioLargo, Inc. invents, develops, and commercializes various platform technologies. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California. Biolargo operates under Chemicals classification in the United States and is traded on OTC Exchange. The company has 275.42 M outstanding shares. More on BioLargo
Moving against BioLargo OTC Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
BioLargo OTC Stock Highlights
| Chairman, CEO and Pres | Dennis Calvert |
| Business Concentration | Materials, Chemicals, Chemicals, Basic Materials (View all Sectors) |
BioLargo [BLGO] is traded as part of a regulated electronic over-the-counter service offered by the NASD. The company currently falls under 'Micro-Cap' category with a current market capitalization of 64.59 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BioLargo's market, we take the total number of its shares issued and multiply it by BioLargo's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. BioLargo conducts business under Chemicals sector and is part of Materials industry. The entity has 275.42 M outstanding shares.
BioLargo currently holds about 1.23 M in cash with (3.94 M) of positive cash flow from operations.
Check BioLargo Probability Of Bankruptcy
Ownership AllocationBioLargo holds a total of 275.42 Million outstanding shares. BioLargo shows 14.7 percent of its outstanding shares held by insiders and 0.04 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check BioLargo Ownership Details
BioLargo Risk Profiles
| Mean Deviation | 2.1 | |||
| Semi Deviation | 2.27 | |||
| Standard Deviation | 4.0 | |||
| Variance | 16.01 |
BioLargo Stock Against Markets
Picking the right benchmark for BioLargo otc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in BioLargo otc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for BioLargo is critical whether you are bullish or bearish towards BioLargo at a given time. Please also check how BioLargo's historical prices are related to one of the top price index indicators.
BioLargo OTC Stock Analysis Notes
About 15.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.03. BioLargo last dividend was issued on the 28th of May 1997. The entity had 1:25 split on the 21st of March 2007. BioLargo, Inc. invents, develops, and commercializes various platform technologies. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California. Biolargo operates under Chemicals classification in the United States and is traded on OTC Exchange. It employs 31 people.The quote for BioLargo is listed on Over The Counter exchange (i.e., OTC), and the entity is not required to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges. For more info on BioLargo please contact Dennis Calvert at 888 400 2863 or go to https://www.biolargo.com.BioLargo Investment Alerts
| BioLargo has some characteristics of a very speculative penny stock | |
| BioLargo had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 2.53 M. Net Loss for the year was (7.08 M) with profit before overhead, payroll, taxes, and interest of 1.1 M. | |
| BioLargo currently holds about 1.23 M in cash with (3.94 M) of positive cash flow from operations. | |
| Roughly 15.0% of the company shares are held by company insiders |
BioLargo Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 64.59 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BioLargo's market, we take the total number of its shares issued and multiply it by BioLargo's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.BioLargo Profitablity
BioLargo's profitability indicators refer to fundamental financial ratios that showcase BioLargo's ability to generate income relative to its revenue or operating costs. If, let's say, BioLargo is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, BioLargo's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of BioLargo's profitability requires more research than a typical breakdown of BioLargo's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (1.29) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.16) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.16. Technical Drivers
As of the 29th of January, BioLargo shows the Downside Deviation of 5.8, mean deviation of 2.1, and Risk Adjusted Performance of 0.0548. BioLargo technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze and collect data for nineteen technical drivers for BioLargo, which can be compared to its peers.BioLargo Price Movement Analysis
Transformation |
The output start index for this execution was zero with a total number of output elements of sixty-one. BioLargo Inverse Tangent Over Price Movement function is an inverse trigonometric method to describe BioLargo price patterns.
BioLargo Outstanding Bonds
BioLargo issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. BioLargo uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most BioLargo bonds can be classified according to their maturity, which is the date when BioLargo has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BIOGEN INC 52 Corp BondUS09062XAD57 | View | |
| BIOGEN INC Corp BondUS09062XAG88 | View | |
| BIOGEN INC Corp BondUS09062XAH61 | View | |
| BIIB 325 15 FEB 51 Corp BondUS09062XAK90 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
BioLargo Predictive Daily Indicators
BioLargo intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of BioLargo otc stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 7817.17 | |||
| Daily Balance Of Power | (1.00) | |||
| Rate Of Daily Change | 0.95 | |||
| Day Median Price | 0.18 | |||
| Day Typical Price | 0.18 | |||
| Period Momentum Indicator | (0.01) | |||
| Relative Strength Index | 50.7 |
BioLargo Forecast Models
BioLargo's time-series forecasting models are one of many BioLargo's otc stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary BioLargo's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Be your own money manager
Our tools can tell you how much better you can do entering a position in BioLargo without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Transaction History Now
Transaction HistoryView history of all your transactions and understand their impact on performance |
| All Next | Launch Module |
BioLargo Corporate Management
Elected by the shareholders, the BioLargo's board of directors comprises two types of representatives: BioLargo inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioLargo. The board's role is to monitor BioLargo's management team and ensure that shareholders' interests are well served. BioLargo's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioLargo's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard Smith | Pres Water | Profile | |
| Randall Moore | Science Engineering | Profile | |
| Steven II | Pres Inc | Profile | |
| CFA II | Chief Officer | Profile |
Other Information on Investing in BioLargo OTC Stock
BioLargo financial ratios help investors to determine whether BioLargo OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioLargo with respect to the benefits of owning BioLargo security.